Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optical topography-based neuropharmacological effect of guanfacine in children with ADHD
jRCTs031190060Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change in oxyhemoglobin concentration signal in right prefrontal cortex CH10. Started Dec 2019; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCTs031190060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190060.